Recent randomized trials, such as EMPEROR-Preserved and DELIVER, have shown that sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce HF hospitalization in patients with LVEF > 40% [23,24]. This evidence concerns the gene SLC5A2 and hydrops fetalis.